/FROM PR NEWSWIRE DALLAS 888-776-3971/
IN MEQ MTC HEA PUB
SU PDT SVY WOM
-- WITH PHOTO -- TO BUSINESS, HEALTH, AND MEDICAL EDITORS:
Aria Diagnostics Announces Name of New Non-Invasive Prenatal Assay -
Harmony Prenatal TestT - and Publication of Study on Specimen
SAN JOSE, Calif., Feb. 6, 2012 /PRNewswire/ -- Aria Diagnostics, a
molecular diagnostics company, today announced that its new prenatal
test has been named the Harmony Prenatal TestT. The test is a directed
non-invasive approach to cell-free DNA (cfDNA) analysis in maternal
blood to detect common trisomies linked to genetic disorders.
(Logo: http://photos.prnewswire.com/prnh/20120109/NY31734LOGO )
"The name perfectly describes Aria's goal of bringing harmony to
patients, medical service providers and healthcare networks by
offering an advanced prenatal test that is highly accurate, accessible
and affordable to a broad population," said Todd Whitson, vice
president of sales and commercial operations at Aria Diagnostics. "The
current landscape of prenatal testing can be cumbersome and confusing.
We hope to streamline the process by providing this simple blood
The Harmony Prenatal Test utilizes new technology which couples
innovative biochemistry, DANSRT, and a proprietary algorithm, FORTET,
to efficiently analyze patients' blood samples.
The company also announces the publication of a study on the effects
of temperature during shipping of blood specimens. The article titled,
"Influence of Temperature during Transportation on Cell-Free DNA
Analysis" is published online in the journal Fetal Diagnosis and
Therapy and available at
publication follows several recent data announcements, including the
peer-reviewed journal publication of three clinical studies in more
than 1,000 patients and the launch of a large scale clinical trial
comparing the Harmony Prenatal Test with the standard first-trimester
screening test in 25,000 women.
The company will be exhibiting information about the Harmony Prenatal
Test and its proprietary technology approach at the Society for
Maternal Fetal Medicine's 32nd Annual Meeting in Dallas, TX, Feb.
About Aria Diagnostics
Aria Diagnostics, Inc., is a molecular diagnostics company committed
to providing safe, highly accurate and affordable prenatal tests for
maternal and fetal health. Led by an experienced team, Aria is using
its proprietary technology to perform a directed analysis of cell-free
DNA in blood. Aria's simple blood test equips pregnant women and their
healthcare providers with reliable information to make decisions
regarding their health, without creating unnecessary stress or
The company began operations in 2010 and is headquartered in San Jose,
Calif. For more information, visit www.ariadx.com.
SOURCE Aria Diagnostics, Inc.
/CONTACT: Traci Tournoux, HealthStar PR, +1-646-722-8830, firstname.lastname@example.org
PRN Photo Desk, email@example.com
/Web Site: http://www.ariadx.com
CO: Aria Diagnostics, Inc.; Society for Maternal Fetal Medicine's 32nd Annual Meeting
ST: California Texas
IN: MEQ MTC HEA PUB
SU: PDT SVY WOM
-- NY47953 --
0000 02/06/2012 14:00:00 EDT http://www.prnewswire.com